Stocksigma LogoStocksigma Logo

Titan Biotech Reports Strong Q2 FY27 Consolidated Net Profit Growth of 61.6% YoY

Titan Biotech reported consolidated revenue from operations of ₹76.46 cr for the quarter ended 30th Sep'26, up 40.7% YoY from ₹54.35 cr and 29.2% QoQ from

Titan Biotech Reports Strong Q2 FY27 Consolidated Net Profit Growth of 61.6% YoY

Titan Biotech Ltd · Outcome · 05 Nov 2026, 9:21 pm

Titan Biotech Reports Strong Q2 FY27 Consolidated Net Profit Growth of 61.6% YoY Titan Biotech reported consolidated revenue from operations of ₹76.46 cr for the quarter ended 30th Sep'26, up 40.7% YoY from ₹54.35 cr and 29.2% QoQ from ₹59.17 cr. Consolidated profit before tax rose 64.1% YoY to ₹15.13 cr. Net profit attributable to shareholders increased 61.6% YoY to ₹12.55 cr compared to ₹7.76 cr in the year-ago period, yielding a basic EPS of ₹3.04. For H1 ended 30th Sep'26, operating cash flows stood at ₹12.88 cr, while consolidated net profit reached ₹23.40 cr.

Original exchange filing (PDF)

More announcements from Titan Biotech Ltd

All Titan Biotech Ltd announcements